We are pleased to announce that Dr Barbara Guinn from University of Hull UK is the winner of the EACR & Novosanis Grant for Cancer Biomarker Detection in Urine.
Novosanis is offering a research grant in collaboration with EACR to stimulate innovative research in cancer biomarker detection using urine as a sample type. Urine can be collected in an...
Novosanis hosted a virtual booth at Eurogin 2021, an international conference focusing on Human Papillomavirus (HPV). Urine, particularly, first-void urine, has potential to screen for...
What a milestone! 8 years and counting. To celebrate our 8th anniversary, we asked our team members to describe Novosanis and their experience in unique words. Teamwork and Innovation were...
In view of the spread of Covid-19 (coronavirus) in our country and across the world, our topmost priority is the health and safety of all our customers and employees. Our team will be...
Researchers at The Sciensano Institute in Belgium will be using urine collected through Colli-Pee ® to understand Chlamydia presence in all ages and genders in the Belgium population.
Novosanis has been co-awarded a CASUS grant, which allows to build a next-generation Colli-Pee ® that will be used in a molecular screening solution for cervical cancer.
A wrap to an exciting and eventful week! Our Product designer, Alejandra Ríos Cortés, represented Novosanis at the Royal Mission, an initiative led by Princess Astrid of Belgium, to boost...
Today, 4 February, is #worldcancerday. Cervical cancer is one of the most preventable forms of cancer if it’s detected early. HPV urine testing can offer a solution for screening next to...
Novosanis
